A Dual-Targeting Peptide Inhibitor Simultaneously Blocking Viral Attachment and Membrane Fusion for Broad-Spectrum Inhibition of SARS-CoV-2
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125729 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wenwen Bi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311215, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Virus Attachment, Antiviral Agents, Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, ZJU-Hangzhou Global Scientific and Technological Innovation Center, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University.
Abstract (Originalsprache)
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with enhanced transmissibility and immune evasion underscores the urgent need for broad-spectrum antiviral therapeutics. In this study, we strategically engineered a novel dual-targeting peptide inhibitor, R1L25HR2, by conjugating the receptor-binding domain (RBD)-targeting peptide R1 with the heptad repeat 1 (HR1)-targeting peptide HR2 through an optimized 25-mer flexible linker (GGGGS)5, aiming to simultaneously block viral attachment and membrane fusion. R1L25HR2 potently and broadly inhibits the infection of SARS-CoV-2 and its emerging variants, including recent circulating strains JN.1 and KP.2, with IC50 values ranging from 5.3 to 253.5 nM, which is significantly more effective than HR2 and R1 alone. Mechanistically, R1L25HR2 inhibits viral attachment and membrane fusion by binding to both RBD and HR1 with low nanomolar affinity. These results highlight the innovative strategy of dual-targeting the RBD and HR1 domains as an effective approach to overcome viral resistance and achieve broad-spectrum antiviral activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311215, China.
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
ORCID-Profile: Wenwen Bi, Jianmin Li
Förderung
- National Natural Science Foundation of China
- ZJU-Hangzhou Global Scientific and Technological Innovation Center
- ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University
Zitieren
APA
Bi, W., Zhu, T., Xu, Y., & Li, J. (2025). A Dual-Targeting Peptide Inhibitor Simultaneously Blocking Viral Attachment and Membrane Fusion for Broad-Spectrum Inhibition of SARS-CoV-2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125729
Vancouver
Bi W, Zhu T, Xu Y, Li J. A Dual-Targeting Peptide Inhibitor Simultaneously Blocking Viral Attachment and Membrane Fusion for Broad-Spectrum Inhibition of SARS-CoV-2. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125729
BibTeX
@article{Bi2025,
author = {Bi, Wenwen and Zhu, Tao and Xu, Yawen and Li, Jianmin},
title = {A Dual-Targeting Peptide Inhibitor Simultaneously Blocking Viral Attachment and Membrane Fusion for Broad-Spectrum Inhibition of SARS-CoV-2},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125729}
}
EUVIMED